Clinical Trials Browser

Phase 2/3 × palbociclib × Clear all

NCT04191499 2026-03-17

INAVO120

Phase 2/3 Active not recruiting

325 enrolled 14 charts 3 FDA

Breast Neoplasms

NCT02692755 2021-09-28

PALINA

Phase 2/3 Completed

35 enrolled 12 charts

Hormone Receptor Positive HER-2 Negative Breast Cancer

NCT02785939 2021-05-27

Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Phase 2/3 Completed

53 enrolled 15 charts

CCND1 Gene Amplification